Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Impact of COVID-19 Mandatory Lockdown Measures on Cognitive and Neuropsychiatric Symptoms in Persons with Alzheimer's Disease in Lima, Peru

Author(s): Nilton Custodio*, Marco Malaga, Rosa Montesinos, Diego Chambergo, Fiorella Baca, Sheila Castro, Juan C. Carbajal, Eder Herrera, David Lira, Monica M. Diaz and Serggio Lanata

Volume 20, Issue 2, 2023

Published on: 06 June, 2023

Page: [80 - 88] Pages: 9

DOI: 10.2174/1567205020666230417103216

Price: $65

Abstract

Background: Neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) worsened during the COVID-19 lockdowns, but their progression thereafter is unknown. We present the first longitudinal study tracking them before, during, and after restrictions.

Objectives: To describe the effect of the COVID-19 mandatory lockdowns on Cognitive and Neuropsychiatric symptoms in patients with Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD).

Methods: Cohort of 48 patients with amnestic MCI and 38 with AD in Lima, Peru. They received three rounds of cognitive (RUDAS, CDR, M@T), behavioral (NPI), and functional (ADCS-ADL) assessments. We assessed the change in score means across the time points and for each domain of NPS and tracked the changes in individual patients.

Results: RUDAS declined 0.9 (SD 1.0) from baseline to lockdown and 0.7 (SD 1.0) after restrictions. M@T declined 1.0 (SD 1.5) from baseline to lockdown and 1.4 (SD 2.0) after restrictions. CDR worsened in 72 patients (83.72%) from baseline to post-lockdown. NPI worsened by 10 (SD 8.3) from baseline to lockdown but improved by 4.8 (SD 6.4) after restrictions. Proportionally, 81.3% of all patients had worsened NPS during the lockdowns, but only 10.7% saw an increase thereafter. Improvement was statistically significant for specific NPS domains except hallucinations, delusions, and appetite changes. Anxiety, irritability, apathy, and disinhibition returned to baseline levels.

Conclusion: Following confinement, cognition continued to decline, but NPS demonstrated either stability or improvement. This highlights the role modifiable risk factors may have on the progression of NPS.

« Previous Next »
[1]
Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol 2010; 9(11): 1118-27.
[http://dx.doi.org/10.1016/S1474-4422(10)70223-4] [PMID: 20934914]
[2]
Pinto T, Lanctôt KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer’s type. Ageing Res Rev 2011; 10(4): 404-12.
[http://dx.doi.org/10.1016/j.arr.2011.01.003] [PMID: 21292041]
[3]
Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis. J Affect Disord 2016; 190: 264-71.
[http://dx.doi.org/10.1016/j.jad.2015.09.069] [PMID: 26540080]
[4]
Murman DL, Colenda CC. The economic impact of neuropsychiatric symptoms in Alzheimer’s disease: can drugs ease the burden? PharmacoEconomics 2005; 23(3): 227-42.
[http://dx.doi.org/10.2165/00019053-200523030-00004] [PMID: 15836005]
[5]
Rattinger GB, Sanders CL, Vernon E, et al. Neuropsychiatric symptoms in patients with dementia and the longitudinal costs of informal care in the Cache County population. Alzheimers Dement 2019; 5(1): 81-8.
[http://dx.doi.org/10.1016/j.trci.2019.01.002] [PMID: 30911601]
[6]
Suárez-González A, Rajagopalan J, Livingston G, Alladi S. The effect of COVID-19 isolation measures on the cognition and mental health of people living with dementia: A rapid systematic review of one year of quantitative evidence. EClinicalMedicine 2021; 39: 101047.
[http://dx.doi.org/10.1016/j.eclinm.2021.101047] [PMID: 34386758]
[7]
Vázquez-Rowe I, Gandolfi A. Peruvian efforts to contain COVID-19 fail to protect vulnerable population groups. Public Health Pract 2020; 1: 100020.
[http://dx.doi.org/10.1016/j.puhip.2020.100020] [PMID: 34171047]
[8]
Custodio N, Castro-Suárez S, Montesinos R, Failoc-Rojas VE, Cruz del Castillo R, Herrera-Perez E. Neuropsychiatric symptoms in patients With Alzheimer’s disease during SARS-COV-2 pandemic in Peru. Am J Alzheimers Dis Other Demen 2021; 36.
[http://dx.doi.org/10.1177/15333175211039089] [PMID: 34416114]
[9]
Simonetti A, Pais C, Jones M, et al. Neuropsychiatric symptoms in elderly with dementia during COVID-19 pandemic: Definition, treatment, and future directions. Front Psychiatry 2020; 11: 579842.
[http://dx.doi.org/10.3389/fpsyt.2020.579842] [PMID: 33132939]
[10]
Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer’s Disease: The neuropsychiatric inventory caregiver distress scale. J Am Geriatr Soc 1998; 46(2): 210-5.
[http://dx.doi.org/10.1111/j.1532-5415.1998.tb02542.x] [PMID: 9475452]
[11]
Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 2): S33-9.
[http://dx.doi.org/10.1097/00002093-199700112-00005] [PMID: 9236950]
[12]
Custodio N, Montesinos R, Chambergo-Michilot D, et al. A functional assessment tool to distinguish controls From Alzheimer’s Disease in Lima, Peru. Am J Alzheimers Dis Other Demen 2022; 37.
[http://dx.doi.org/10.1177/15333175221104354] [PMID: 35656899]
[13]
Custodio N, Montesinos R, Lira D, et al. Validation of the RUDAS for the identification of dementia in illiterate and low-educated older adults in Lima, Peru. Front Neurol 2020; 11(May): 374.
[http://dx.doi.org/10.3389/fneur.2020.00374] [PMID: 32477248]
[14]
Custodio N, Lira D, Herrera-Perez E, et al. The memory alteration test discriminates between cognitively healthy status, mild cognitive impairment and Alzheimer’s disease. Dement Geriatr Cogn Disord Extra 2014; 4(2): 314-21.
[http://dx.doi.org/10.1159/000365280] [PMID: 25298775]
[15]
Hughes CP, Berg L, Danziger W, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140(6): 566-72.
[http://dx.doi.org/10.1192/bjp.140.6.566] [PMID: 7104545]
[16]
Dyer O. Covid-19: Peru’s official death toll triples to become world’s highest. BMJ 2021; 373: n1442.
[http://dx.doi.org/10.1136/bmj.n1442] [PMID: 34088698]
[17]
Chen ZC, Liu S, Gan J, et al. The impact of the COVID-19 pandemic and lockdown on mild cognitive impairment, Alzheimer’s disease and dementia with lewy bodies in China: A 1-year follow-up study. Front Psychiatry 2021; 12: 711658.
[http://dx.doi.org/10.3389/fpsyt.2021.711658] [PMID: 34393864]
[18]
Vernuccio L, Sarà D, Inzerillo F, et al. Effect of COVID-19 quarantine on cognitive, functional and neuropsychiatric symptoms in patients with mild cognitive impairment and dementia. Aging Clin Exp Res 2022; 34(5): 1187-94.
[http://dx.doi.org/10.1007/s40520-022-02113-z] [PMID: 35325450]
[19]
Cagnin A, Di Lorenzo R, Marra C, et al. Behavioral and psychological effects of coronavirus disease-19 quarantine in patients with dementia. Front Psychiatry 2020; 11(578015): 578015.
[http://dx.doi.org/10.3389/fpsyt.2020.578015] [PMID: 33033486]
[20]
Canevelli M, Valletta M, Toccaceli Blasi M, et al. Facing Dementia During the COVID ‐19 Outbreak. J Am Geriatr Soc 2020; 68(8): 1673-6.
[http://dx.doi.org/10.1111/jgs.16644] [PMID: 32516441]
[21]
Cohen G, Russo MJ, Campos JA, Allegri RF. COVID-19 epidemic in Argentina: Worsening of behavioral symptoms in elderly subjects with dementia living in the community. Front Psychiatry 2020; 11: 866.
[http://dx.doi.org/10.3389/fpsyt.2020.00866] [PMID: 33005158]
[22]
Ibanez A, Santamaria-Garcia H, Guerrero Barragan A, et al. The impact of SARS‐CoV‐2 in dementia across Latin America: A call for an urgent regional plan and coordinated response. Alzheimers Dement (N Y) 2020; 6(1): e12092.
[http://dx.doi.org/10.1002/trc2.12092] [PMID: 33283036]
[23]
Davis M, O’Connell T, Johnson S, et al. Estimating Alzheimer’s disease progression rates from normal cognition through mild cognitive impairment and stages of dementia. Curr Alzheimer Res 2018; 15(8): 777-88.
[http://dx.doi.org/10.2174/1567205015666180119092427] [PMID: 29357799]
[24]
Mendoza-Ruvalcaba NM, Gutiérrez-Herrera R, López C, et al. Impact of quarantine due to COVID-19 pandemic on health and lifestyle conditions in older adults from Centro American countries. PLoS One 2022; 17(5): e0264087.
[http://dx.doi.org/10.1371/journal.pone.0264087] [PMID: 35544521]
[25]
Wei G, Diehl-Schmid J, Matias-Guiu JA, et al. The effects of the COVID-19 pandemic on neuropsychiatric symptoms in dementia and carer mental health: An international multicentre study. Sci Rep 2022; 12(1): 2418.
[http://dx.doi.org/10.1038/s41598-022-05687-w] [PMID: 35165292]
[26]
Babulal GM, Torres VL, Acosta D, et al. The impact of COVID-19 on the well-being and cognition of older adults living in the United States and Latin America. EClinicalMedicine 2021; 35: 100848.
[http://dx.doi.org/10.1016/j.eclinm.2021.100848] [PMID: 33997742]
[27]
Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020; 7(7): 611-27.
[http://dx.doi.org/10.1016/S2215-0366(20)30203-0] [PMID: 32437679]
[28]
Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun 2022; 101: 93-135.
[http://dx.doi.org/10.1016/j.bbi.2021.12.020] [PMID: 34973396]
[29]
Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. J Neurol Sci 2022; 434: 120162.
[http://dx.doi.org/10.1016/j.jns.2022.120162] [PMID: 35121209]
[30]
Toniolo S, Scarioni M, Di Lorenzo F, et al. Dementia and COVID-19, a bidirectional liaison: Risk factors, biomarkers, and optimal health care. J Alzheimers Dis 2021; 82(3): 883-98.
[http://dx.doi.org/10.3233/JAD-210335] [PMID: 34092646]
[31]
Gan J, Liu S, Wu H, et al. The impact of the COVID-19 pandemic on Alzheimer’s disease and other dementias. Front Psychiatry 2021; 12(July): 703481.
[http://dx.doi.org/10.3389/fpsyt.2021.703481] [PMID: 34335338]
[32]
Borges-Machado F, Barros D, Ribeiro Ó, Carvalho J. The effects of COVID-19 home confinement in dementia care: Physical and cognitive decline, severe neuropsychiatric symptoms and increased caregiving burden. Am J Alzheimers Dis Other Demen 2020; 35.
[http://dx.doi.org/10.1177/1533317520976720] [PMID: 33295781]
[33]
Manca R, De Marco M, Venneri A. The impact of COVID-19 infection and enforced prolonged social isolation on neuropsychiatric symptoms in older adults with and without dementia: A review. Front Psychiatry 2020; 11: 585540.
[http://dx.doi.org/10.3389/fpsyt.2020.585540] [PMID: 33192732]
[34]
Cohen G, Russo MJ, Campos JA, Allegri RF. Living with dementia: Increased level of caregiver stress in times of COVID-19. Int Psychogeriatr 2020; 32(11): 1377-81.
[http://dx.doi.org/10.1017/S1041610220001593] [PMID: 32729446]
[35]
Liew TM. Neuropsychiatric symptoms in early stage of Alzheimer’s and non-Alzheimer’s dementia, and the risk of progression to severe dementia. Age Ageing 2021; 50(5): 1709-18.
[http://dx.doi.org/10.1093/ageing/afab044] [PMID: 33770167]
[36]
Peters ME, Schwartz S, Han D, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry 2015; 172(5): 460-5.
[http://dx.doi.org/10.1176/appi.ajp.2014.14040480] [PMID: 25585033]
[37]
Ettcheto M, Olloquequi J, Sánchez-López E, et al. Benzodiazepines and related drugs as a risk factor in Alzheimer’s disease dementia. Front Aging Neurosci 2020; 11: 344.
[http://dx.doi.org/10.3389/fnagi.2019.00344] [PMID: 31969812]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy